The medicine for Allergan plc's (AGN) - Get Report ills is already in the companies pipeline.

UBS published a note Wednesday saying that the problems that caused a 20% dip in Allergan's share price over the past 12 months are behind the company. 

Management is being aggressive on cost-cutting measures. Additionally, three key events over the next 6 months should turn investor sentiment for the company positive in 2018.

The firm expects positive phase 3 testing data for the company's chronic migraine treatment, approval and a solid label for Allergan's uterine fibroid treatment Esmya, and positive phase 3 data for Abicipar, Allergan's macular degeneration treatment. 

Allergan still has soft top-line guidance between $15 billion and $15.3 billion, which lags UBS' own estimate of $15.7 billion, and Wall Street's consensus $15.6 billion expectations. But with cost cuts between $300 million and $400 million expected, there is still reason to believe the company can beat bottom-line expectations. 

UBS maintained its "buy" rating and $250 price target for the company, a 42% upside over the stock's previous close. 

Allergan is a holding in Jim Cramer's Action Alerts PLUS Charitable Trust Portfolio. Want to be alerted before Jim Cramer buys or sells the stock? Learn more now.

More of What's Trending on TheStreet: